This inventor holds 1 USPTO granted patent and 2 published patent applications. Top assignees: Children's National Medical Center, University System of Maryland. Active years: 2026.
Company Filing History:


Years Active: 2026
Title: Michele Saruwatari: Innovator in Wound Treatment Technology
Introduction
Michele Saruwatari is a notable inventor based in Washington, DC, recognized for his contributions to medical technology. He holds a patent for a sprayable tissue adhesive that enhances wound treatment through innovative materials and methods. His work focuses on improving healing processes and reducing complications associated with tissue damage.
Latest Patents
Michele Saruwatari's most recent patent is titled "Sprayable tissue adhesive with biodegradation for wound treatment." This invention involves viscoelastic poly(lactide-co-caprolactone) (PLCL) mixtures designed for effective wound healing. The PLCL mixtures provide an improved anti-fibrotic yet tissue-adhesive polymer sealant, which can be applied to various wounds resulting from both surgical and non-surgical tissue damage. He has been granted 1 patent for this innovative solution.
Career Highlights
Throughout his career, Michele has worked with esteemed institutions such as the University System of Maryland and Children's National Medical Center. His experience in these organizations has allowed him to develop and refine his inventions, contributing significantly to the field of medical technology.
Collaborations
Michele Saruwatari has collaborated with notable professionals in his field, including Peter Kofinas and Anthony Sandler. These partnerships have facilitated the advancement of his research and the successful development of his patented technologies.
Conclusion
Michele Saruwatari is a pioneering inventor whose work in wound treatment technology has the potential to transform medical practices. His innovative approach to creating biodegradable tissue adhesives showcases the importance of research and collaboration in advancing healthcare solutions.